BACKGROUND: We determined the prevalence and factors associated with hyperlactatemia among HIV patients admitted on the emergency ward of a national hospital in Uganda. OBJECTIVE: We were specifically interested in knowing whether there was an association between clinically significant hyperlactatemia and concurrent antiretroviral therapy (ART) use. METHODS: A cross sectional descriptive study enrolled 303 HIV infected patients at a national referral hospital between March and April 2008. We consecutively recruited all eligible HIV infected patients above 18 years admitted on the emergency ward. Data were collected on socio-demographic, clinical and laboratory characteristics. Lactate levels were measured using the Accutrend® portable lactate analyser. Data analysis was performed using Stata 10.0; P-value of < 0.05 was considered to be significant. RESULTS: Three hundred and three HIV infected patients were recruited. Prevalence of hyperlactatemia (lactate ≥2.5mmol/L) was 252 (83.2%). Clinically significant hyperlactatemia (lactate ≥4mmol/L) was present in 105/303(34.6%) patients. There was no association between use of ART and clinically significant hyperlactatemia. In the multivariate analysis, body weakness 1.91 (1.09-3.35), skin rash 3.18 (1.11-9.10) and tachypnoea 1.04 (1.01-1.07) were independently associated with clinically significant hyperlactatemia. CONCLUSION: There was a high prevalence of clinically significant hyperlactatemia among HIV infected patients but it was not associated with concurrent antiretroviral use.
BACKGROUND: We determined the prevalence and factors associated with hyperlactatemia among HIVpatients admitted on the emergency ward of a national hospital in Uganda. OBJECTIVE: We were specifically interested in knowing whether there was an association between clinically significant hyperlactatemia and concurrent antiretroviral therapy (ART) use. METHODS: A cross sectional descriptive study enrolled 303 HIV infectedpatients at a national referral hospital between March and April 2008. We consecutively recruited all eligible HIV infectedpatients above 18 years admitted on the emergency ward. Data were collected on socio-demographic, clinical and laboratory characteristics. Lactate levels were measured using the Accutrend® portable lactate analyser. Data analysis was performed using Stata 10.0; P-value of < 0.05 was considered to be significant. RESULTS: Three hundred and three HIV infectedpatients were recruited. Prevalence of hyperlactatemia (lactate ≥2.5mmol/L) was 252 (83.2%). Clinically significant hyperlactatemia (lactate ≥4mmol/L) was present in 105/303(34.6%) patients. There was no association between use of ART and clinically significant hyperlactatemia. In the multivariate analysis, body weakness 1.91 (1.09-3.35), skin rash 3.18 (1.11-9.10) and tachypnoea 1.04 (1.01-1.07) were independently associated with clinically significant hyperlactatemia. CONCLUSION: There was a high prevalence of clinically significant hyperlactatemia among HIV infectedpatients but it was not associated with concurrent antiretroviral use.
Authors: J Fellay; K Boubaker; B Ledergerber; E Bernasconi; H Furrer; M Battegay; B Hirschel; P Vernazza; P Francioli; G Greub; M Flepp; A Telenti Journal: Lancet Date: 2001-10-20 Impact factor: 79.321
Authors: Richard Ssekitoleko; Relana Pinkerton; Rose Muhindo; Sanjay Bhagani; Christopher C Moore Journal: Am J Trop Med Hyg Date: 2011-10 Impact factor: 2.345
Authors: Richard Ssekitoleko; Shevin T Jacob; Patrick Banura; Relana Pinkerton; David B Meya; Steven J Reynolds; Nathan Kenya-Mugisha; Harriet Mayanja-Kizza; Rose Muhindo; Sanjay Bhagani; W Michael Scheld; Christopher C Moore Journal: Crit Care Med Date: 2011-10 Impact factor: 7.598
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: James A Berkley; Brett S Lowe; Isaiah Mwangi; Thomas Williams; Evasius Bauni; Saleem Mwarumba; Caroline Ngetsa; Mary P E Slack; Sally Njenga; C Anthony Hart; Kathryn Maitland; Mike English; Kevin Marsh; J Anthony G Scott Journal: N Engl J Med Date: 2005-01-06 Impact factor: 91.245
Authors: F Bonnet; M Bonarek; P Morlat; P Mercié; M Dupon; M C Gemain; D Malvy; N Bernard; J L Pellegrin; J Beylot Journal: Clin Infect Dis Date: 2003-05-02 Impact factor: 9.079
Authors: F N Ssali; M R Kamya; F Wabwire-Mangen; S Kasasa; M Joloba; D Williams; R D Mugerwa; J J Ellner; J L Johnson Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1998-12-15
Authors: Christopher C Moore; Shevin T Jacob; Relana Pinkerton; David B Meya; Harriet Mayanja-Kizza; Steven J Reynolds; W Michael Scheld Journal: Clin Infect Dis Date: 2008-01-15 Impact factor: 9.079